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Objective: Plasma total adiponectin reveals a sexual dimorphism indicating that gonadal steroids may be
involved in its secretion and/or metabolism. However, results from previous reports are conﬂicting and
data regarding the inﬂuence of ovarian steroids on adiponectin’s multimer forms are scarce. The
objective of the study was to assess if total adiponectin and its isoforms are affected by the changes of
estradiol and progesterone during the normal menstrual cycle and the association of total adiponectin
and its isoforms with the gonadal steroid levels.
Materials/methods: Quantitative determination of plasma adiponectin and its multimers was conducted
in the three phases of an ovulatory cycle in 13 premenopausal women, in the follicular phase of 10 more
premenopausal women, in 20 postmenopausal women and in 21 men. Moreover, serum levels of FSH,
LH, prolactin, estradiol, progesterone, and testosterone, sex hormone binding globulin, glucose, and
insulin were measured.
Results: The circulating levels of total adiponectin and its multimers were not affected by the normal
variation of estradiol and progesterone across the ovulatory menstrual cycle. In the whole number of
participants, the total adiponectin and high molecular weight adiponectin levels were signiﬁcantly
different between genders and associated positively with age and sex hormone binding globulin levels,
and negatively with testosterone and progesterone levels and the waist/hip ratio. In the multiple logistic
regression analysis, after adjustment for age, gender, and sex hormone binding globulin and proges-
terone levels, signiﬁcant predictors of total adiponectin levels were the waist/hip ratio and testosterone
levels, and of high molecular weight adiponectin the testosterone levels.
Conclusions: Normal menstrual cycle ovarian steroids are not involved directly in the regulation of
secretion and/or metabolism of total adiponectin and its multimers. Testosterone seems to be respon-
sible for the adiponectin’s sexual dimorphism.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).available testosterone; CRP,
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Adiponectin is produced by the adipose tissue and is secreted
into the bloodstream where it accounts for up to 0.05% of total
serum protein and circulates as a low molecular weight (LMW)
trimer (w65 kDa), mean molecular weight (MMW) hexamer
(w150 kDa) and high molecular weight (HMW) multimers (w280
andw420 kDa) [1]. HMW isoforms appear to be the most biologi-
cally active form of adiponectin, being related to reduced abdominal
fat and high basal lipid oxidation [2]. Recent studies also suggest
that HMW adiponectin and the ratio of HMW to TA are associated
with insulin sensitivity, antiatherogenic activities, metabolic syn-
drome and the prediction of cardiovascular disease [3].
Plasma adiponectin reveals a sexual dimorphism, with females
having signiﬁcantly higher circulating levels of TA and HMWnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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whereas the levels of MMW and LMW forms are comparable be-
tween sexes [7]. This sexual dimorphism leads to the hypothesis
that adiponectin secretion and/or metabolism are regulated by
gonadal steroids. However, previous reports, applying a diversity of
study models to investigate the potential effect of sex steroids
exerted on adiponectin secretion, are conﬂicting.
Previous studies [9,10], but not all [4,11], have shown signiﬁ-
cantly higher circulating adiponectin concentrations in post-
menopausal than in premenopausal and pregnant women.
Speciﬁcally, serum concentrations of TA and HMW adiponectin
were highest in postmenopausal women and lowest in pregnant
women, whereas between the three groups MMW and LMW iso-
forms were comparable [10]. Existing data regarding the associa-
tion between estradiol (E2) and adiponectin levels are conﬂicting
[11,12], indicating that in women, besides E2, other factors such
as age [6] and alterations in the androgen-to-estrogen ratio [5] may
contribute to the mentioned differences. These might be the reason
for the low adiponectin levels reported in women with polycystic
ovary syndrome (PCOS) and elevated total testosterone (TT) level,
although coexistent obesity and/or insulin resistance cannot be
excluded [13]. Androgens also seem to inﬂuence plasma TA levels.
Hypogonadal men, compared to eugonadal, have signiﬁcantly
higher plasma adiponectin levels, which are reduced by testos-
terone replacement therapy [14]. Similarly, in normal men experi-
mental testosterone deﬁciency increased plasma TA levels, an effect
that was suppressed when testosterone replacement therapy was
also given [15]. However, supraphysiologic testosterone adminis-
tration resulted in decreased plasma adiponectin levels [15].
Previous studies investigating variations of circulating adipo-
nectin concentrations during the menstrual cycle are limited and
have shown contradictory data. Moreover, only total circulating
adiponectin levels were measured and the speculation that mainly
the HMW isoform of adiponectin is sensitive to female sex steroids
changes [12] has not been further investigated. As far as we know,
there is only one study where circulating adiponectin multimer
forms concentrations were measured at the early phase of the
menstrual cycle [16]. Therefore, we investigated whether sex hor-
mones affect not only plasma TA levels but also adiponectin mul-
timer forms in all phases of a normal menstrual cycle. A normal
menstrual cycle corresponds to a three-step model with low E2
levels in the follicular phase, increased E2 levels in the preovulatory
phase and increased E2 plus progesterone levels in the luteal phase
with the androgens remaining unchanged. Moreover, we assessed
the associations between blood testosterone and estradiol with
total adiponectin, HMW adiponectin and the HMW/total adipo-
nectin ratio in healthy pre- and postmenopausal women and men.
Subjects and methods
Subjects
In the study, twenty-three premenopausal women were
enrolled with mean (SD) age 34.0  4.7 and range 27e40 years
with normal body weight (BMI 22.3  2.2) and regular menstrual
cycle. All women were healthy and none of them had received
hormonal or any other medical treatment for at least 6 months
prior to this study. Fasting blood samples were collected between
8:00 and 10:00 am. From thirteen out of the twenty-three pre-
menopausal women blood was obtained at the three phases of a
28-days menstrual cycle, deﬁned by the menses onset: follicular
(4the5th day), ovulatory (11the12th day) and luteal phase (20the
21st day). From the other ten premenopausal women blood was
obtained only at the follicular phase of the menstrual cycle (4the
5th day). Five of them were withdrawn from the study, in four thestudied menstrual cycle was anovulatory and in one the last time
point serum samples were lost.
Blood was also obtained from twenty postmenopausal women
(more than 1 year from the last menstrual period) and twenty-one
men. All were healthy and none of them had received any medi-
cation during the last six months prior to this study.
Postmenopausal women and men had mean age 56.0  3.0 (range
51e63) and 37.0  3.4 (range 32e44) years, respectively. Before
blood sampling each subject underwent a thorough physical ex-
amination. Body weight and height, waist circumference (WC) and
blood pressure were measured as previously described [17]. Mean
arterial blood pressure (MBP) was calculated as follows:
MBP ¼ diastolic BP þ (1/3 systolic BP).
Laboratory parameters measurement
After sampling in EDTA or serum tubes, blood was centrifuged at
1465 g for 7 min and aliquots were immediately frozen at 86 C
until assayed. Blood sampleswere analyzed for FSH, LH, E2, TSH, FT4,
PRL, PRG, testosterone, SHBG, albumin, glucose, insulin and HbA1c
by an auto analyzer (Olympus 600; Medicon, Athens, Greece) using
standard techniques. Serum free testosterone (FT) and bioavailable
testosterone (bio-T) were calculated from serum total testosterone,
SHBG and albumin concentrations as previously described [17]. Free
androgen index (FAI)was computed as the ratio of total testosterone
(in nmol/L) to SHBG (in nmol/L) concentration. The homeostasis
model assessment of insulin resistance (HOMA-R) index was
calculated as plasma insulin (in l U/mL) plasma glucose (inmg/dL)
divided by 22.5  18. Total adiponectin and multimers’ concentra-
tion were quantiﬁed by ELISA (Bühlmann Labs, Switzerland) in the
same assay. The amount of HMW, MMWand LMWadiponectin was
calculated according to the manufacturer’s instructions. The intra-
assay CV was 5% for total adiponectin, 6% for MMW þ HMW, and
5.7% for HMW adiponectin.
Written informed consent was obtained from all participants
and the study protocol was reviewed and approved by the Scientiﬁc
and Ethics Committee of the School of Medicine, University of
Thessaly.
Statistical analysis
Results forquantitative variables are expressed asmean standard
deviation (SD) unless otherwise indicated. Data for qualitative vari-
ables were described as numbers and/or percentages. Student t test or
the ManneWhitney U-test was used to estimate differences between
mean values, as appropriate. Comparison of frequencies was per-
formed using X2 or Fisher’s exact test. One way ANOVA with Bonfer-
roni correction was used to determine trends of the repeated
measures on the 13 premenopausal women during the menstrual
cycle and differences across the groups. Spearman’s coefﬁcient was
used to test for bivariate correlations. Multiple logistic regressions
were used to examine the association between total adiponectin,
HMWadiponectin or HMW/TA ratio as a dependent variable and age,
gender, abdominal obesity, SHBG, progesterone, and FT or TT levels as
independent variables. A probability value of p< 0.05 was considered
statistically signiﬁcant. Analyses were performed using SPSS for win-
dows version 17.0 (SPSS Inc Chicago, IL).
Results
In the thirteen women studied at the three phases of their
menstrual cycle, serum prolactin was normal (20.8  8.2) and the
concentrations of E2 and P showed the typical patterns of an
ovulatory cycle (Table 1). The duration of the study cycle ranged
between 25 and 28 days (26.9  1.3 days). In contrast to the
Table 1
Serum levels of gonadal steroids, total adiponectin and its multimers and insulin









Estradiol (pg/ml) 55.6  19.9 313  144 162  75 0.001
Progesterone (ng/ml) 0,51  0,27 0.65  0.40 16.9  5.1 0.001
Total testosterone (ng/ml) 0.35  0.21 0.39  0.20 0.34  0.25 0.841
Free testosterone (ng/dl) 0.47  0.33 0.48  0.33 0.35  0.19 0.453
Bio-testosterone (ng/dl) 12.0  8.3 11.9  8.0 8.2  5.2 0.334
Free androgen index 0.66  0.61 1.08  1.75 0.54  0.60 0.445
Total adiponectin (mg/ml) 7.12  2.09 6.99  2.34 7.65  2.62 0.898
HMW adiponectin (mg/ml) 4.71  2.30 4.89  2.79 5.82  3.05 0.791
MMW adiponectin (mg/ml) 0.67  0.51 0.89  0.53 0.64  0.21 0.633
LMW adiponectin (mg/ml) 1.74  0.52 1.22  0.54 1.19  0.44 0.196
HMW/total adiponectin ratio 0.63  0.17 0.66  0.17 0.72  0.16 0.681
HOMA-R 2.1  2.0 1.6  0.8 1.9  0.7 0.664
a p value across the three phases by one-way ANOVA.
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observed in the blood levels of total, free and bioavailable testos-
terone, and FAI at the three phases of the menstrual cycle (Table 1).
Similarly, no signiﬁcant change was detected in the blood levels of
total adiponectin and its isoforms as well as the HMW/TA ratio.
Insulin resistance, as indicated by the HOMA-R, was comparable at
the three phases of the menstrual cycle.
Table 2 shows the anthropometric characteristics, biochemical
variables, and hormone and adiponectin levels of 23 premeno-
pausal women studied in the early follicular phase, 20 post-
menopausal women and 21 men. Postmenopausal women were
older compared to premenopausal women who had comparable
age to the men. BMI and WC were normal in premenopausal
women and men, whereas postmenopausal women were over-
weight with central adiposity. Mean blood pressure was signiﬁ-
cantly higher in men compared to both groups of women. All three
groups had normal mean levels of CRP and were euthyroid. Blood
levels of FSH, LH and prolactin were different between groups, as
expected (data not shown). SHBG levels were signiﬁcantly lower in
men compared to both groups of women, who had comparable
levels. Insulin levels and insulin resistance index were comparable
between the three groups. Total, free and bioavailable testosterone
levels as well as FAI (data not shown) were signiﬁcantly higher in
men, as expected, compared to pre- and postmenopausal women,Table 2
Clinical and laboratory characteristics in premenopausal women (follicular phase), postm
Variable Premenopausal women
N 23
Age (range) (years) 34 (24e41)
BMI (kg/m2) 22.3  2.15
Waist circumference (cm) 78.4  6.2
Smoking (yes/no) 5/18
CRP (mg/dl) 0.30  0.3
SHBG (nmol/L) 62.4  26.5
HOMA-R 1.9  1.6
Total testosterone (ng/ml) 0.36  0.16
Free testosterone (ng/dl) 0.47  0.31
Bio-testosterone (ng/dl) 12.2  7.8
Estradiol (pg/ml) 56.7  29.7
Total adiponectin (mg/ml) 7.09  1.87
HMW adiponectin (mg/ml) 4.74  2.06
MMW adiponectin (mg/ml) 0.71  0.46
LMW adiponectin (mg/ml) 1.65  0.51
HMW/total adiponectin ratio 0.64  0.15
HMW adiponectin (%) 63.5  15.3
MMW adiponectin (%) 11.2  8.2
LMW adiponectin (%) 25.2  11.1
a p value across the three groups by one-way ANOVA.who had comparable androgen levels. E2 levels were comparable in
men and postmenopausal women but signiﬁcantly lower compared
to premenopausal women levels.
Total, HMW and MMW adiponectin levels were comparable
between pre- and postmenopausal women but signiﬁcantly lower
in men (Table 2, Figure 1), whereas no difference was found in the
LMW adiponectin levels or in the HMW/TA ratio between the
studied groups. Similarly, the percent distribution of HMW, MMW
and LMW adiponectin isoforms did not show any signiﬁcant dif-
ference between the three groups.
In the group of women studied in the three phases of the
menstrual cycle, no correlation was found between adiponectin or
its isoforms levels and sex steroids, insulin and glucose levels or
body composition and HOMA-R. By contrast, in the whole number
of participants, serum levels of TA and HMW adiponectin were
correlated positively with age and SHBG levels and negatively with
androgen levels, progesterone levels, andW/H ratio. In the multiple
logistic regression analysis, after adjustment for age, gender, and
SHBG and progesterone levels, signiﬁcant predictors for the blood
TA, were the waist/Hip ratio and androgens (p ¼ 0.016). W/H ratio
and FT levels account for 59.5% of the variation in TA levels, with the
former predicting 52.1% of the variation. When HMW adiponectin
was used as the outcome variable, androgens were the only pre-
dictors (p ¼ 0.001), accounting for 31.1% of the variation in HMW
adiponectin levels. HMW/TA ratio was not predicted by any of the
variables included in the model.
Discussion
The sexual dimorphism in plasma adiponectin levels in both
humans [4,5] and animals [6e8] obviously raises the question as to
whether gonadal steroids are involved in this issue. In vitro and
experimental data demonstrate that both androgens and estrogens
exert an inﬂuence on circulating adiponectin levels [4,6,18]. More-
over, a recent in vitro study has shown that progesterone stimulates
the secretion of adiponectin from 3T3-L1 adipocytes [18]. Our study
is the ﬁrst one examining the effect of estrogens and of estrogens
plus progesterone on the levels of HMW, MMWand LMW isoforms
of adiponectin throughout a normal menstrual cycle. Our results
demonstrate that during the three phases of an ovulatory men-
strual cycle, thementioned sex steroids variation does not affect the
circulating levels of total adiponectin and its multimer forms.enopausal women, and men
Postmenopausal women Men p valuea
20 21
56 (51e63) 37 (32e44)
27.3  5.1 24.9  1.82 0.001
89.3  10.2 94.6  5.7 0.001
4/16 9/12 NS
0.51  0.5 0.25  0.2 0.074
64.3  27.2 29.2  11.5 0.003
2.1  1.3 2.2  1.0 0.820
0.27  0.17 5.4  1.7 0.001
0.40  0.28 11.7  3.4 0.001
10.1  7.1 308  83 0.001
11.7  10.6 24.9  9.6 0.001
6.78  3.32 2.59  0.81 0.001
4.22  2.54 1.48  0.85 0.001
1.11  0.88 0.56  0.26 0.027
1.45  1,90 0.55  0.32 0.056
0.61  0.19 0.54  0.18 0.345
61.3  19.1 54.0  17.7 0.346
17.8  12.1 23.6  12.7 0.071
20.9  15.1 22.4  11.9 0.779
Fig. 1. Mean (SEM) serum total adiponectin levels in the follicular phase of 23 pre-
menopausal women, postmenopausal women and men * P < 0.01 compared to pre-
and postmenopausal women by one-way ANOVA analysis.
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data [18e23], showing that normal changes of estrogen and pro-
gesterone during a normal cycle do not affect total adiponectin
levels. The effect of E2 administered in ovariectomized premeno-
pausal women on total adiponectin was similar [11]. Moreover, in a
recent in vitro study [24] in human fat cells, where adiponectin is
mainly synthesized, increasing concentrations of estradiol did not
change either adiponectin mRNA expression and secretion or
intracellular protein expression of HMW, MMW and LMW adipo-
nectin isoforms. However, the absence of a suppressive effect of
estrogens on TA and its multimer levels in our case, even though a
signiﬁcant increase of E2 alone or combined with progesterone was
evident, is in contrast with published results indicating a sup-
pressive effect of estrogens on adiponectin production in mice and
in 3T3-Li adipocytes [6,18], and an independent negative associa-
tion of E2 with TA levels in a group of 121 pre- and postmenopausal
womenwithout a history of diabetes [25]. The comparable levels of
TA and its multimers that we found in pre- and post-menopausal
women are incompatible with the suppressive effect of estrogens,
despite the fact that a signiﬁcant difference in E2 levels was present.
The fact that treatment of postmenopausal womenwith E2 resulted
in an increase, no change or a decrease in TA [11,12,26] could
probably be explained by differences in the design of each study
and the presence of a number of adiponectin confounding factors
such as age [9], androgens [14,15], prolactin [6], HOMA-R [27], body
weight [6], physical activity [23,28], and food consumption [6], all
of whichwere stable in our study. The negative association between
the HMW and MMW of adiponectin forms and E2 or progesterone
levels reported in a prior study [10] is also in discordance with our
results and may possibly be explained by the inclusion in the study
of pregnant women with higher and long-lasting estrogen and
progesterone levels in this study.
In both humans [4e6] and rodents [7,8], blood TA levels were
found lower in males compared to BMI and age-matched females
and this has been proposed as being due to the effect of male sex
hormones. In line with these data we found that TA levels were
signiﬁcantly lower in men compared to pre- and postmenopausal
women. Moreover, in the multiple regression analysis of all three
groups together, W/H ratio and testosterone levels were indepen-
dent negative predictors of TA levels. When HMW adiponectin was
used as the dependent variable, androgenswere the only predictors.
Our results are in accordance with published data suggesting an
inhibitory effect of androgens on circulating total adiponectin
concentrations. Castration in male mice and gonadectomy in rats of
both sexes was followed by an increase in plasma adiponectin levels
that was reversed when testosterone was administered [4,8],
ablating the difference in TA levels between males and females [8]while maintaining HMW adiponectin levels [8]. The inhibitory ef-
fect of androgens on the levels of total adiponectin was equal using
testosterone enanthate and a non-aromatizable androgen, indi-
cating that estrogens are not involved in this effect [8]. Similarly, in
cultured 3T3-L1 adipocytes, both testosterone and dihy-
drotestosterone reduced the secretion of adiponectin in the culture
media [4], indicating a negative regulation on adipocytes that was
also observed in humans. Notably, the experimentally-induced
testosterone deﬁciency in normal men was followed within days
by a signiﬁcant increase in TA levels, an effect that was prevented by
testosterone replacement without changing the BMI [15], while
female-to-male transsexuals experienced a reduction in adipo-
nectin following testosterone administration [29]. Moreover, in
boys during pubertal development an androgens-associated pro-
gressive decline of adiponectin has been demonstrated, resulting in
lower levels compared to girls after the completion of puberty [30].
Studies in adults [25,31] and adolescents [30] show that adi-
ponectin decreases with increasing degree of obesity and the
reduction appears to precede the actual development of insulin
resistance, metabolic derangements and diabetes [31]. Speciﬁcally,
in epidemiologic studies central fat mass is more closely associated
with the development of insulin resistance and cardiovascular
disease [32]. W/H ratio is a reliable index of central obesity and here
we show that W/H ratio is an independent negative predictor of
total adiponectin, in accordance with a number of published data
[12,25], but not all [8,33]. The administered testosterone-induced
reduction of visceral and total-body fat mass in young [29] and
older men [34] and of circulating adiponectin concentrations in
hypogonadal [7,14,35] and eugonadal [15] men may indicate an
inﬂuence of testosterone on the secretion and/or metabolism of
adiponectin in a way that seems to be directionally concurrent to
adiposity.
Our ﬁnding that the concentration of adiponectin HMW form is
lower in men compared to pre- and postmenopausal women is
consistent with previous reports [4,7], suggesting a sexual dimor-
phism of adiponectin expression. It has been reported that testos-
terone selectively impedes the secretion of HMW adiponectin [7],
and this action is mainly considered responsible for the sexual
dimorphism of adiponectin in both human and rodents and could
in part explain why men have a higher risk of insulin resistance and
are less sensitive to pioglitazone.
Whether sex steroids have a direct effect on adiponectin
expression, cellular trafﬁcking and/or metabolism by adipocytes is
not known. Recently, published data have shown that estrogens and
androgens signiﬁcantly increase and decrease, respectively,
peroxisome proliferator-activated receptor g (PPARg) protein
expression in 3T3-L1 mature adipocytes only after long-term
exposure [36]. This information, in conjunction with the observa-
tion that PPARg agonists increase HMWoligomers from adipocytes
by regulating a pair of molecular chaperons in the endoplasmic
reticulum [37], could indicate that gonadal steroids may function as
indirect opposite regulators of HMWoligomer secretion inﬂuenced
by intracellular PPARg agonists or other factors. It has been also
proposed that adiponectin is secreted from adipocytes through two
distinct secretory pathways, a constitutive and a regulated one [38].
The involvement of Rho-kinase in the estradiol-induced inhibition
of total adiponectin secretion has also been suggested, in vitro, in
differentiating 3T3-L1 adipocytes but not in the progesterone-
induced stimulation of adiponectin secretion [18]. However, these
results must be carefully assessed due to the fact that higher con-
centrations of estradiol and progesterone were used compared to
respective blood levels in menstruating women. The comparable
levels of HMWmultimers in the three phases of normal menstrual
cycles, as demonstrated in our study, may indicate the need for
more ovulating women recruitment and longer time exposure to
K. Chatzidimitriou et al. / Journal of Clinical & Translational Endocrinology 2 (2015) 61e65 65estrogens. More research is needed to elucidate the mechanisms of
the inﬂuence of sex steroids on adiponectin secretion from adipose
tissue.Conﬂict of interest
The authors declare they have no conﬂicts of interest.
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